Liquidia (NASDAQ:LQDA) Rating Increased to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA) to a strong-buy rating in a report issued on Wednesday morning, Zacks.com reports.

Several other brokerages have also recently commented on LQDA. Bank of America reduced their target price on shares of Liquidia from $24.00 to $23.00 and set a buy rating for the company in a report on Tuesday, August 20th. Oppenheimer initiated coverage on Liquidia in a report on Tuesday, June 25th. They issued a market perform rating for the company. HC Wainwright dropped their target price on Liquidia from $32.00 to $29.00 and set a buy rating on the stock in a report on Tuesday, August 20th. Raymond James raised Liquidia from an outperform rating to a strong-buy rating in a research report on Monday, August 19th. Finally, BTIG Research lowered their price target on Liquidia from $29.00 to $25.00 and set a buy rating on the stock in a research report on Monday, August 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $24.00.

Liquidia Stock Performance

Shares of LQDA opened at $10.03 on Wednesday. The firm has a market cap of $766.43 million, a P/E ratio of -6.43 and a beta of 0.22. Liquidia has a twelve month low of $5.71 and a twelve month high of $16.99. The firm’s 50 day moving average price is $10.44 and its two-hundred day moving average price is $12.22.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, sell-side analysts anticipate that Liquidia will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at $3,914,234.17. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction that occurred on Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,422 shares of company stock valued at $256,998 over the last 90 days. 31.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in Liquidia by 491.2% in the 1st quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock valued at $681,000 after purchasing an additional 38,369 shares during the period. Vestal Point Capital LP bought a new stake in shares of Liquidia in the fourth quarter valued at about $12,331,000. Kynam Capital Management LP grew its stake in shares of Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after acquiring an additional 698,324 shares in the last quarter. BNP Paribas Financial Markets increased its position in Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after acquiring an additional 125,315 shares during the period. Finally, Swiss National Bank acquired a new stake in Liquidia in the 1st quarter worth about $1,325,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).